A phase I/II study of pixantrone (BBR 2778) [Cell Therapeutics] in combination with cyclophosphamide, vincristine and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma

Trial Profile

A phase I/II study of pixantrone (BBR 2778) [Cell Therapeutics] in combination with cyclophosphamide, vincristine and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Apr 2011

At a glance

  • Drugs Cyclophosphamide; Pixantrone; Prednisone; Vincristine
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 Apr 2011 Results have been published in Leukaemia & Lymphoma, according to a Cell Therapeutics media release.
    • 19 Jan 2007 Status change
    • 18 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top